The decrease in the ratio of false positive results obtained in the sequential use of LDCT scan and the TM panel (CA-62, CEA and CYFRA 21-1) is of great clinical importance in the context of improving Low-Dose CT lung cancer organized screening and reducing potential side effects, associated with repeated CT scans or other unnecessary invasive diagnostic methods. The gene discussed is CEACAM5; the disease is lung carcinoma.